Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Yuhan Corporation (000100:KRX), powered by AI.
Yuhan Corporation is currently trading at ₩78,900. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Yuhan Corporation on Alpha Lenz.
Yuhan Corporation's P/E ratio is 30.4.
“Yuhan Corporation trades at a P/E of 30.4 (premium valuation) with solid ROE of 8.8%.”
Ask for details →Yuhan Corporation is a prominent entity in the pharmaceutical industry, dedicated to the research, development, and distribution of a wide range of medical products and services. Headquartered in South Korea, Yuhan Corporation is involved in manufacturing prescription drugs, over-the-counter medications, and active pharmaceutical ingredients, supporting both domestic and international markets. In addition to pharmaceuticals, the company also explores biotechnological innovations and manufacturing partnerships to diversify its product offerings. Yuhan Corporation plays a critical role in improving public health by investing in cutting-edge research and fostering collaborations with global pharmaceutical leaders to bring innovative therapies to market. Its comprehensive portfolio addresses various medical needs, influencing sectors from general healthcare to specialized treatments. With a strong emphasis on corporate responsibility and sustainability, Yuhan Corporation prioritizes ethical business practices and environmental stewardship, contributing to its stature as a leading name in the pharmaceutical landscape.
“Yuhan Corporation trades at a P/E of 30.4 (premium valuation) with solid ROE of 8.8%.”
Ask for details →Yuhan Corporation (ticker: 000100) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 2,038 employees. Market cap is $6.3T.
The current price is ₩78,900 with a P/E ratio of 30.36x and P/B of 2.55x.
ROE is 8.81% and operating margin is 4.77%. Annual revenue is $2.2T.